These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 23380999)

  • 1. Breast cancer: Tamoxifen--when more might be better.
    Caldas C; Tannock IF
    Nat Rev Clin Oncol; 2013 Mar; 10(3):125-6. PubMed ID: 23380999
    [No Abstract]   [Full Text] [Related]  

  • 2. The duration of adjuvant tamoxifen therapy.
    Bilimoria MM; Jordan VC
    Cancer Treat Res; 1998; 94():181-93. PubMed ID: 9587688
    [No Abstract]   [Full Text] [Related]  

  • 3. The impact of systemic therapy following ductal carcinoma in situ.
    Eng-Wong J; Costantino JP; Swain SM
    J Natl Cancer Inst Monogr; 2010; 2010(41):200-3. PubMed ID: 20956830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis.
    Amir E; Seruga B; Niraula S; Carlsson L; Ocaña A
    J Natl Cancer Inst; 2011 Sep; 103(17):1299-309. PubMed ID: 21743022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Letrozole vs. placebo after adjuvant tamoxifen in postmenopausal breast cancer: the MA-17 study].
    Gori S; Anastasi P; Marrocolo F
    Suppl Tumori; 2004; 3(4):S27-31. PubMed ID: 15206206
    [No Abstract]   [Full Text] [Related]  

  • 6. Tamoxifen and the endometrium.
    Barakat RR
    Cancer Treat Res; 1998; 94():195-207. PubMed ID: 9587689
    [No Abstract]   [Full Text] [Related]  

  • 7. Exemestane as first-line therapy in postmenopausal women with recurrent or metastatic breast cancer.
    Glück S
    Am J Clin Oncol; 2010 Jun; 33(3):314-9. PubMed ID: 19730353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Adverse reactions to anti-hormonal therapy affects adherence].
    von Wachenfeldt A; Andersson A; Fornander T; Isaksson Friman E; Johnsson A; Uddbom E; Uttermalm AC
    Lakartidningen; 2017 Feb; 114():. PubMed ID: 28221399
    [No Abstract]   [Full Text] [Related]  

  • 9. Tamoxifen, raloxifene and the prevention of breast cancer.
    Bentrem DJ; Craig Jordan V
    Minerva Endocrinol; 2002 Jun; 27(2):127-39. PubMed ID: 11961504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors.
    Rugo HS
    Ann Oncol; 2008 Jan; 19(1):16-27. PubMed ID: 17693420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast cancer trial stopped early.
    Josefson D
    BMJ; 1998 Apr; 316(7139):1187. PubMed ID: 9583923
    [No Abstract]   [Full Text] [Related]  

  • 12. Aromatase inhibitors for the treatment of breast cancer: is tamoxifen of historical interest only?
    Van Poznak CH; Hayes DF
    J Natl Cancer Inst; 2006 Sep; 98(18):1261-3. PubMed ID: 16985239
    [No Abstract]   [Full Text] [Related]  

  • 13. The breast cancer prevention trial: should women at risk take tamoxifen?
    McKeon VA
    J Obstet Gynecol Neonatal Nurs; 1999; 28(6 Suppl 1):34-8. PubMed ID: 10608495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Tamoxifen and breast cancer: is everything known already?].
    Marchetti P; Porzio G; Trapasso T; Baldi PL; Ficorella C
    Tumori; 1998; 84(6):A1-5. PubMed ID: 10080686
    [No Abstract]   [Full Text] [Related]  

  • 15. Switching to aromatase inhibitors in early breast cancer.
    Boccardo F; Rubagotti A
    Lancet; 2007 Feb; 369(9561):533-5. PubMed ID: 17307082
    [No Abstract]   [Full Text] [Related]  

  • 16. Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials.
    Vogel VG; Costantino JP; Wickerham DL; McCaskill-Stevens W; Clarfeld RB; Grant MD; Wolmark N
    J Natl Cancer Inst Monogr; 2010; 2010(41):181-6. PubMed ID: 20956826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomized controlled trial].
    Noël G; Mezziou M; Mazeron JJ
    Cancer Radiother; 1999; 3(6):524-5. PubMed ID: 10630169
    [No Abstract]   [Full Text] [Related]  

  • 18. The importance of nonpharmacogenetic factors in endocrine therapy.
    McCowan C; Thompson AM
    Pharmacogenomics; 2012 Apr; 13(6):721-8. PubMed ID: 22515614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant and extended adjuvant use of aromatase inhibitors: reducing the risk of recurrence and distant metastasis.
    Gligorov J; Pritchard K; Goss P
    Breast; 2007 Dec; 16 Suppl 3():S1-9. PubMed ID: 18061455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects].
    de Cremoux P; Diéras V; Poupon MF; Magdelénat H; Sigal-Zafrani B; Fourquet A; Pierga JY
    Bull Cancer; 2004 Dec; 91(12):917-27. PubMed ID: 15634633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.